Welcome to our dedicated page for Ernexa Therapeutics SEC filings (Ticker: ERNAW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ernexa Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ernexa Therapeutics's regulatory disclosures and financial reporting.
Ernexa Therapeutics Inc. furnished an updated investor presentation as part of a current report on Form 8-K. The July 2026 presentation, attached as Exhibit 99.1, updates materials first posted in February 2026 and will also be available on the company’s investor relations website.
The company states that it routinely uses its website to distribute important information, including press releases, investor presentations and financial data, and offers email alerts when new materials are posted. The information in this item and Exhibit 99.1 is being provided as “furnished,” not “filed,” under the Exchange Act.
Ernexa Therapeutics Inc. furnished an updated investor presentation as part of a current report on Form 8-K. The July 2026 presentation, attached as Exhibit 99.1, updates materials first posted in February 2026 and will also be available on the company’s investor relations website.
The company states that it routinely uses its website to distribute important information, including press releases, investor presentations and financial data, and offers email alerts when new materials are posted. The information in this item and Exhibit 99.1 is being provided as “furnished,” not “filed,” under the Exchange Act.
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the May 6, 2026 record date, there were 1,166,333 common shares outstanding, and 619,741 shares, or about 53.13%, were represented, establishing a quorum.
Stockholders elected five directors to serve until the 2027 annual meeting, ratified Haskell & White LLP as independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. No other matters were brought to a vote.
Ernexa Therapeutics Inc. reported the results of its 2026 Annual Meeting of Stockholders. As of the May 6, 2026 record date, there were 1,166,333 common shares outstanding, and 619,741 shares, or about 53.13%, were represented, establishing a quorum.
Stockholders elected five directors to serve until the 2027 annual meeting, ratified Haskell & White LLP as independent auditor for the 2026 fiscal year, and approved the 2026 Ernexa Therapeutics Inc. Omnibus Equity Incentive Plan. No other matters were brought to a vote.
Ernexa Therapeutics Inc. announced that Senior Vice President of Finance Sandra Gurrola has submitted her resignation, effective July 3, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.
After her resignation becomes effective, Ms. Gurrola has agreed to provide transition assistance on a part-time basis for up to 10 hours per week through the filing of Ernexa’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa has begun a search for her successor and plans to use additional outside support to help with finance, accounting, and reporting until a replacement is appointed.
Ernexa Therapeutics Inc. announced that Senior Vice President of Finance Sandra Gurrola has submitted her resignation, effective July 3, 2026. The company states that her resignation is not due to any disagreement over operations, policies, or practices.
After her resignation becomes effective, Ms. Gurrola has agreed to provide transition assistance on a part-time basis for up to 10 hours per week through the filing of Ernexa’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Ernexa has begun a search for her successor and plans to use additional outside support to help with finance, accounting, and reporting until a replacement is appointed.
Ernexa Therapeutics Inc. received an amendment to a Schedule 13G filed by Clear Street LLC that terminates Clear Street's reporting obligation. The amendment states Clear Street's beneficial ownership is 0 shares, representing 0.0% of the common stock and therefore below the 5% reporting threshold.
The amendment explains no reporting obligation existed at the time of the original filing and is signed by John DiBacco, Head of Markets Trading on 05/20/2026.
Ernexa Therapeutics Inc. received an amendment to a Schedule 13G filed by Clear Street LLC that terminates Clear Street's reporting obligation. The amendment states Clear Street's beneficial ownership is 0 shares, representing 0.0% of the common stock and therefore below the 5% reporting threshold.
The amendment explains no reporting obligation existed at the time of the original filing and is signed by John DiBacco, Head of Markets Trading on 05/20/2026.
Freebird Partners LP and related reporting persons amend a Schedule 13G/A to report beneficial ownership of Ernexa Therapeutics Inc. common stock. The filing shows 120,412 shares beneficially owned, representing 9.9% of the class, based on an aggregate outstanding share count of 1,205,328 shares as of May 8, 2026. The reported position combines 81,417 owned shares and shares issuable on exercise of warrants (including 52,000 common warrants and 15,015 pre-funded warrants), with 28,020 warrant shares excluded because of a contractual 9.99% beneficial ownership limitation. The coverages reflect the issuer's 1-for-25 reverse stock split effected May 4, 2026.
Freebird Partners LP and related reporting persons amend a Schedule 13G/A to report beneficial ownership of Ernexa Therapeutics Inc. common stock. The filing shows 120,412 shares beneficially owned, representing 9.9% of the class, based on an aggregate outstanding share count of 1,205,328 shares as of May 8, 2026. The reported position combines 81,417 owned shares and shares issuable on exercise of warrants (including 52,000 common warrants and 15,015 pre-funded warrants), with 28,020 warrant shares excluded because of a contractual 9.99% beneficial ownership limitation. The coverages reflect the issuer's 1-for-25 reverse stock split effected May 4, 2026.
Ernexa Therapeutics Inc. disclosure amends prior Schedule 13G filings to report that John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, share beneficial ownership of 66,751 shares of Common Stock, representing 5.6% of the class.
The filing explains the share count includes (i) 46,445 shares held by the Trust, (ii) 306 shares issuable upon exercise of pre-funded warrants at an exercise price of $1.8750 per share, and (iii) 20,000 shares issuable upon exercise of warrants at $17.00 per share. The percentage is calculated using an aggregate of 1,186,639 shares outstanding (including 20,306 shares issuable within 60 days), and notes the impact of the 1-for-15 and 1-for-25 reverse stock splits.
Ernexa Therapeutics Inc. disclosure amends prior Schedule 13G filings to report that John D. Halpern and Katherine H. Halpern, as trustees of the John D. Halpern Revocable Trust, share beneficial ownership of 66,751 shares of Common Stock, representing 5.6% of the class.
The filing explains the share count includes (i) 46,445 shares held by the Trust, (ii) 306 shares issuable upon exercise of pre-funded warrants at an exercise price of $1.8750 per share, and (iii) 20,000 shares issuable upon exercise of warrants at $17.00 per share. The percentage is calculated using an aggregate of 1,186,639 shares outstanding (including 20,306 shares issuable within 60 days), and notes the impact of the 1-for-15 and 1-for-25 reverse stock splits.
Ernexa Therapeutics Inc. reports that Bleichroeder LP and affiliated filers beneficially own 80,000 common shares, equal to 6.86% of the outstanding common stock as of 03/31/2026.
The filing states a 4.99% limitation on warrant exercises; absent that limitation Bleichroeder would be deemed owner of 160,000 shares (about 12.84%). The reporting persons are Bleichroeder Holdings LLC, Bleichroeder LP and Andrew Gundlach.
Ernexa Therapeutics Inc. reports that Bleichroeder LP and affiliated filers beneficially own 80,000 common shares, equal to 6.86% of the outstanding common stock as of 03/31/2026.
The filing states a 4.99% limitation on warrant exercises; absent that limitation Bleichroeder would be deemed owner of 160,000 shares (about 12.84%). The reporting persons are Bleichroeder Holdings LLC, Bleichroeder LP and Andrew Gundlach.
Ernexa Therapeutics Inc. disclosed a Schedule 13G showing Clear Street LLC beneficially owns 149,499 shares of Common Stock, representing 12.8% of the class as of 05/05/2026.
The filing reports sole voting and sole dispositive power over the 149,499 shares. The filing is signed by John DiBacco, Head of Markets Trading for Clear Street LLC.
Ernexa Therapeutics Inc. disclosed a Schedule 13G showing Clear Street LLC beneficially owns 149,499 shares of Common Stock, representing 12.8% of the class as of 05/05/2026.
The filing reports sole voting and sole dispositive power over the 149,499 shares. The filing is signed by John DiBacco, Head of Markets Trading for Clear Street LLC.
Ernexa Therapeutics Inc. amendment updates beneficial ownership for Shameek Konar, Victoria Konar and Regolith Capital Investments LP, reporting 118,342 shares (shared voting and dispositive power) and 48,000 warrants exercisable into common stock. The filing states these amounts reflect a 1-for-15 reverse split (June 10, 2025) and a 1-for-25 reverse split (May 4, 2026).
The filing calculates a 9.7% stake based on 1,214,333 shares outstanding (including 48,000 shares deemed outstanding pursuant to Rule 13-3(d)(1)(i)).
Ernexa Therapeutics Inc. amendment updates beneficial ownership for Shameek Konar, Victoria Konar and Regolith Capital Investments LP, reporting 118,342 shares (shared voting and dispositive power) and 48,000 warrants exercisable into common stock. The filing states these amounts reflect a 1-for-15 reverse split (June 10, 2025) and a 1-for-25 reverse split (May 4, 2026).
The filing calculates a 9.7% stake based on 1,214,333 shares outstanding (including 48,000 shares deemed outstanding pursuant to Rule 13-3(d)(1)(i)).
Ernexa Therapeutics Inc. is asking stockholders to elect five directors, ratify Haskell & White LLP as auditor, and approve a new 2026 Omnibus Equity Incentive Plan at its virtual 2026 annual meeting on July 1, 2026, at 11:00 a.m. Eastern Time.
Holders of Ernexa common stock as of May 6, 2026, when 1,166,333 shares were outstanding, may vote online, by phone, by mail, or electronically during the meeting. The proxy details board structure, committee responsibilities, governance policies, and significant ownership, including a 32.53% stake held by Charles Cherington.
The filing also outlines executive pay, with 2025 total compensation of $888,813 for CEO Sanjeev Luther and $329,372 for Senior Vice President of Finance Sandra Gurrola, plus equity incentive arrangements and severance and change-in-control protections.
Ernexa Therapeutics Inc. is asking stockholders to elect five directors, ratify Haskell & White LLP as auditor, and approve a new 2026 Omnibus Equity Incentive Plan at its virtual 2026 annual meeting on July 1, 2026, at 11:00 a.m. Eastern Time.
Holders of Ernexa common stock as of May 6, 2026, when 1,166,333 shares were outstanding, may vote online, by phone, by mail, or electronically during the meeting. The proxy details board structure, committee responsibilities, governance policies, and significant ownership, including a 32.53% stake held by Charles Cherington.
The filing also outlines executive pay, with 2025 total compensation of $888,813 for CEO Sanjeev Luther and $329,372 for Senior Vice President of Finance Sandra Gurrola, plus equity incentive arrangements and severance and change-in-control protections.